The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

Multiple myeloma (MM) is a hematologic cancer characterized by accumulation of malignant plasma cells in the bone marrow. To date, no definitive cure exists for MM and resistance to current treatments is one of the major challenges of this disease. The DNA helicase BLM, whose depletion or mutation c...

Full description

Bibliographic Details
Main Authors: Sara Ovejero, Elena Viziteu, Laure Dutrieux, Julie Devin, Yea-Lih Lin, Elina Alaterre, Michel Jourdan, Jihane Basbous, Guilhem Requirand, Nicolas Robert, Hugues de Boussac, Anja Seckinger, Dirk Hose, Laure Vincent, Charles Herbaux, Angelos Constantinou, Philippe Pasero, Jérôme Moreaux
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
BLM
DNA damage
replication stress
drug resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.983181/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.983181/full

Similar Items